An insight of novel pharmacological therapies in hypertrophic cardiomyopathy

Medicinal Chemistry

Volumn 7, Issue 4, 2011, Pages 275-285

  Orenes Piñero, Esteban ^a   Hernández Romero, Diana ^a   Jover, Eva ^a   De La Morena, Gonzalo ^a   Valdés, Mariano ^a   Marín, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Calcineurin inhibitors; Fibrosis; Hypertrophic cardiomyopathy; Losartan; Nacetylcysteine; Perhexiline; Spironolactone; Statins

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; BENAZEPRIL; BENAZEPRILAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CANDESARTAN; CYCLOSPORIN A; DILTIAZEM; DISOPYRAMIDE; ENALAPRIL; ENALAPRILAT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; OLMESARTAN; PERHEXILINE; PERINDOPRIL; SPIRONOLACTONE; TACROLIMUS; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ARTICLE; BRADYCARDIA; CONGESTIVE HEART FAILURE; CONSTIPATION; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART MUSCLE RELAXATION; HEART VENTRICLE FILLING; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; LIVER TOXICITY; LUNG CONGESTION; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYNCOPE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR AGENTS; FIBROSIS; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; VENTRICULAR REMODELING;

EID: 79959353577     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796150941     Document Type: Article

References (103)

1. Maron, B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA, 2002, 287, 1308-1320. (Pubitemid 34250486)
2. Tsybouleva, N.; Zhang, L.; Chen, S.; Patel, R.; Lutucuta, S.; Nemoto, S.; DeFreitas, G.; Entman, M.; Carabello, B.A.; Roberts, R.; Marian, A.J. Aldosterone, through novel signalling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation, 2004, 109, 1284-1291. (Pubitemid 38372788)
3. Elliott, P.; McKenna, W.J. Hypertrophic cardiomyopathy. Lancet, 2004, 363, 1881-1891. (Pubitemid 38748646)
4. Maron, B.J.; Niimura, H.; Casey, S.A.; Soper, M.K.; Wright, G.B.; Seidman, J.G.; Seidman, C.E. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J. Am. Coll. Cardiol., 2001, 38, 315-321. (Pubitemid 32721755)
5. Ho, C.Y.; Seidman, C.E. A contemporary approach to hypertrophic cardiomyopathy. Circulation, 2006, 113, 858-862.
6. Marian, A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet, 2000, 355, 58-60. (Pubitemid 30072190)
7. Shimoyama, M.; Hayashi, D.; Zou, Y.; Takimoto, E.; Mizukami, M.; Monzen, K.; Kudoh, S.; Hiroi, Y.; Yazaki, Y.; Nagai, R.; Komuro, I. Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with saltsensitive hypertension. Circulation, 2000, 102, 1996-2004.
8. Lim, D.S.; Lutucuta, S.; Bachireddy, P.; Youker, K.; Evans, A.; Entman, M.; Roberts, R.; Marian, A.J. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 2001, 103, 789-791. (Pubitemid 32163874)
9. Senthil, V.; Chen, S.N.; Tsybouleva, N.; Halder, T.; Nagueh, S.F.; Willerson, J.T.; Roberts, R.; Marian, A.J. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ. Res., 2005, 97, 285-292. (Pubitemid 41105455)
10. Lombardi, R.; Rodriguez, G.; Chen, S.N.; Ripplinger, C.M.; Li, W.; Chen, J.; Willerson, J.T.; Betocchi, S.; Wickline, S.A.; Efimov, I.R.; Marian, A.J. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation, 2009, 119, 1398-1407.
11. Teekakirikul, P.; Eminaga, S.; Toka, O.; Alcalai, R.; Wang, L.; Wakimoto, H.; Nayor, M.; Konno, T.; Gorham, J.M.; Wolf, C.M.; Kim, J.B.; Schmitt, J.P.; Molkentin, J.D.; Norris, R.A.; Tager, A.M.; Hoffman, S.R.; Markwald, R.R.; Seidman, C.E.; Seidman, J.G. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J. Clin. Invest., 2010, 120, 3520-3529.
12. Marian, A.J. Experimental Therapies in Hypertrophic Cardiomyopathy. J Cardiovasc. Transl. Res., 2009, 2, 483-492.
13. Maron, B.J.; Shen, W.K.; Link, M.S.; Epstein, A.E.; Almquist, A.K.; Daubert, J.P.; Bardy, G.H.; Favale, S.; Rea, R.F.; Boriani, G.; Estes, N.A. 3rd; Spirito, P. Efficacy of implantable cardioverterdefibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med., 2000, 342, 365-373. (Pubitemid 30084534)
14. Ommen, S.R.; Maron, B.J.; Olivotto, I.; Maron, M.S.; Cecchi, F.; Betocchi, S.; Gersh, B.J.; Ackerman, M.J.; McCully; R.B.; Dearani, J.A.; Schaff, H.V.; Danielson, G.K.; Tajik, A.J.; Nishimura, R.A. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2005, 46, 470-476. (Pubitemid 41040288)
15. Boltwood, C.M. Jr; Chien, W.; Ports, T. Ventricular tachycardia complicating alcohol septal ablation. N. Engl. J. Med., 2004, 351, 1914-1915. (Pubitemid 39426334)
16. Horowitz, J.D.; Chirkov, Y.Y. Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation. Circulation, 2010, 122, 1547-1549.
17. Zafarullah, M.; Li, W.Q.; Sylvester, J.; Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol. Life Sci., 2003, 60, 6-20. (Pubitemid 36223114)
18. Cambronero, F.; Marín, F.; Roldán, V.; Hernández- Romero, D., Valdés, M.; Lip, G.Y. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur. Heart J., 2009, 30, 139-151.
19. Marian, A.J. Modifier genes for hypertrophic cardiomyopathy. Curr. Opin. Cardiol., 2002, 17, 242-252. (Pubitemid 34553628)
20. Lele, S.S.; Thomson, H.L.; Seo, H.; Belenkie, I.; McKenna, W.J.; Frenneaux, M.P. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation, 1995, 92, 2886-2894.
21. Shirani, J.; Pick, R.; Roberts, W.C.; Maron, B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol., 2000, 35, 36-44. (Pubitemid 30061256)
22. Varnava, A.M.; Elliott, P.M.; Mahon, N.; Davies, M.J.; McKenna, W.J. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am. J. Cardiol., 2001, 88, 275-279. (Pubitemid 32721955)
23. Sakata, Y.; Masuyama, T.; Yamamoto, K.; Nishikawa, N.; Yamamoto, H.; Kondo, H.; Ono, K.; Otsu, K.; Kuzuya, T.; Miwa, T.; Takeda, H.; Miyamoto, E.; Hori, M. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation, 2000, 102, 2269-2275.
24. Berridge, M.J. Calcium signalin and cell proliferation. Bioessay, 1995, 17, 491-500.
25. Molkentin, J.D.; Lu, J.R.; Antos, C.L. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell, 1998, 93, 215-228. (Pubitemid 28180855)
26. Sussman, M.A.; Lim, H.W.; Gude, N.; Taigen, T.; Olson, E.N.; Robbins, J.; Colbert, M.C.; Gualberto, A.; Wieczorek, D.F.; Molkentin, J.D. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science, 1998, 281, 1690-1693. (Pubitemid 28435588)
27. Brown, R.D.; Ambler, S.K.; Mitchell, M.D.; Long, C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 657-687. (Pubitemid 40261821)
28. Jugdutt, B.I. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr. Drug Targets Cardiovasc. Haematol. Disord., 2003, 3, 1-30. (Pubitemid 36244902)
29. Debold, E.P.; Schmitt, J.P.; Patlak, J.B.; Beck, S.E.; Moore, J.R.; Seidman, J.G.; Seidman, C.E.; Warshaw, D.M. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, 284-291.
30. Ho, C.Y.; Sweitzer, N.K.; McDonough, B.; Maron, B.J.; Casey, S.A.; Seidman, J.G.; Seidman, C.E.; Solomon, S.D. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation, 2002, 105, 2992-2997. (Pubitemid 34693832)
31. Belus, A.; Piroddi, N.; Scellini, B.; Tesi, C.; Amati, G.D.; Girolami, F.; Yacoub, M.; Cecchi, F.; Olivotto, I.; Poggesi, C. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J. Physiol., 2008, 586, 3639-3644.
32. Ashrafian, H.; Redwood, C.; Blair, E.; Watkins, H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet., 2003, 19, 263-268. (Pubitemid 36507008)
33. Unno, K.; Isobe, S.; Izawa, H.; Cheng, X.W.; Kobayashi, M.; Hirashiki, A.; Yamada, T.; Harada, K.; Ohshima, S.; Noda, A.; Nagata, K.; Kato, K.; Yokota, M.; Murohara, T. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur. Heart J., 2009, 30, 1853-1862.
34. Petersen, S.E.; Jerosch-Herold, M.; Hudsmith, L.E.; Robson, M.D.; Francis, J.M.; Doll, H.A.; Selvanayagam, J.B.; Neubauer, S.; Watkins, H. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation, 2007, 115, 2418-2425. (Pubitemid 46717964)
35. Lee, L.; Campbell, R.; Scheuermann-Freestone, M.; Taylor, R.; Gunaruwan, P.; Williams, L.; Ashrafian, H.; Horowitz, J.; Fraser, A.G.; Clarke, K.; Frenneaux, M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation, 2005, 112, 3280-3288. (Pubitemid 43739373)
36. Abozguia, K.; Elliott, P.; McKenna, W.; Phan, T.T.; Nallur-Shivu, G.; Ahmed, I.; Maher, A.R.; Kaur, K.; Taylor, J.; Henning, A.; Ashrafian, H.; Watkins, H.; Frenneaux, M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation, 2010, 122, 1562-1569.
37. Thaman, R.; Elliott, P.M.; Shah, J.S.; Mist, B.; Williams, L.; Murphy, R.T.; McKenna, W.J.; Frenneaux, M.P. Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2005, 46, 883-892. (Pubitemid 41224814)
38. Musat, D.; Sherrid, M.V. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Anadolu. Kardiyol. Derg., 2006, 6, 9-17. (Pubitemid 46099681)
39. Hagège, A.A.; Desnos, M. New trends in treatment of hypertrophic cardiomyopathy. Arch. Cardiovasc. Dis., 2009, 102, 441-447
40. Kaltenbach, M.; Hopf, R.; Kober, G.; Bussmann, W.D.; Keller, M.; Petersen, Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br. Heart J., 1979, 42, 35-42. (Pubitemid 9241500)
41. Sherrid, M.V. Pharmacologic treatment of symptomatic hypertrophic cardiomyopathy. In: Diagnosis and Management of Hypertrophic Cardiomyopathy, Maron, B.J., Ed. Blackwell-Futura, London, 2004, pp. 200-219.
42. Bonow, R.O.; Rosing, D.R.; Bacharach, S.L.; Green, M.V.; Kent, K.M.; Lipson, L.C.; Maron, B.J.; Leon, M.B.; Epstein, S.E. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation, 1981, 64, 787-796. (Pubitemid 11030133)
43. Udelson, J.E.; Bonow, R.O.; O'Gara, P.T.; Maron, B.J.; Van Lingen, A.; Bacharach, S.L.; Epstein, S.E. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation, 1989, 79, 1052-1060. (Pubitemid 19129187)
44. Dimitrow, P.P.; Krzanowski, M.; Nitankowski, R.; Szczeklik, A.; Dubiel, J.S. The effect of verapamil on response of coronary vasomotion to handgrip exercise in symptomatic patients with hypertrophic cardiomyopathy. Cardiovasc. Drugs Ther., 2001, 15, 331-337. (Pubitemid 33121987)
45. Epstein, S.E.; Rosing, D.R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation, 1981, 64, 437-441. (Pubitemid 11061609)
46. Ito T, Suwa M, Imai M, Hozumi T, Tonari S, Kitaura Y. Acute effects of diltiazem on regional left ventricular diastolic filling dynamics in patients with hypertrophic cardiomyopathy as assessed by color kinesis. Circ. J. 2004; 68:1035-1040. (Pubitemid 39540134)
47. Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M, Potter JD, Schultheiss HP, Tschöpe C. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur. J. Heart Fail. 2006; 8: 115-121. (Pubitemid 43240843)
48. McTaggart DR. Diltiazem reverses tissue Doppler velocity abnormalities in pre-clinical hypertrophic cardiomyopathy. Heart Lung Circ. 2004; 13: 39-40. (Pubitemid 40903141)
49. Sherrid, M.V.; Barac, I.; McKenna, W.J.; Elliott, P.M.; Dickie, S.; Chojnowska, L.; Casey, S.; Maron, B.J. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2005, 45, 1251-1258. (Pubitemid 40523146)
50. McKenna, W.J.; Behr, E.R. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart, 2002, 87, 169-176. (Pubitemid 34098386)
51. Pollick, C.G.K.; Blaschke, T.F.; Nelson, W.L.; Turner-Tamiyasu, K.; Briskin, V.; Popp, R.L. The cardiac effects of d- and ldisopyramide in normal subjects: a noninvasive study. Circulation, 1982, 66, 447-453. (Pubitemid 12084998)
52. Yamazaki, T.; Komuro, I.; Kudoh, S.; Zou, Y.Z.; Shiojima, I.; Mizuno, T.; Takano, H.; Hiroi, Y.; Ueki, K.; Tobe, K.; Kadowaki, T.; Nagai, R.; Yazaki, Y. Angiotensin-II partly mediates mechanical stress-induced cardiac-hypertrophy. Circ. Res., 1995, 77, 258-265.
53. Porter, K.E.; Turner, N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther., 2009, 123, 255-278.
54. Song, J.C.; White, C.M. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet., 2002, 41, 207-224. (Pubitemid 34415839)
55. Kelly, J.G.; O'Malley, K. Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin. Pharmacokinet., 1990, 19, 177-196. (Pubitemid 20281449)
56. Brilla, C.G.; Funck, R.C.; Rupp, H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation, 2000, 102, 1388-1393.
57. Schwartzkopff, B.; Brehm, M.; Mundhenke, M.; Strauer, B.E. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension, 2000, 36, 220-225. (Pubitemid 30626992)
58. Qin, Y.; Yasuda, N.; Akazawa, H.; Ito, K.; Kudo, Y.; Liao, C.H.; Yamamoto, R.; Miura, S.I.; Saku, K.; Komuro, I. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation. Hypertens. Res., 2009, 32, 875-883.
59. Zaman, M.A.; Oparil, S.; Calhoun, D.A. Drugs targeting the reninangiotensin- aldosterone system. Nat. Rev. Drug Discov., 2002, 1, 621-636. (Pubitemid 37368827)
60. Li, L.; Zhou, N.; Gong, H.; Wu, J.; Lin, L.; Komuro, I.; Ge, J.; Zou, Y. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens. Res., 2010, [Epub ahead of print].
61. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol., 2004; 6: 499-506. (Pubitemid 38786592)
62. Yamazaki, T.; Suzuki, J.; Shimamoto, R.; Tsuji, T.; Ohmoto- Sekine, Y.; Ohtomo, K.; Nagai, R. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int. Heart J., 2007, 48, 715-724.
63. Araujo, A.Q.; Arteaga, E.; Ianni, B.M.; Buck, P.C.; Rabello, R.; Mady, C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am. J. Cardiol., 2005, 96, 1563-1567. (Pubitemid 41690179)
64. Stowasser, M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin. Exp. Pharmacol. Physiol., 2001, 28, 783-791. (Pubitemid 32947172)
65. Luft, FC. Mechanisms and cardiovascular damage in hypertension. Hypertension, 2001, 37, 594-598. (Pubitemid 32199033)
66. Rajagopalan, S.; Duquaine, D.; King, S.; Pitt, B.; Patel, P. Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis. Circulation, 2002, 105, 2212-2216. (Pubitemid 34517167)
67. Pitt, B.; Stier, C.T. Jr; Rajagopalan, S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst., 2003, 4, 164-168. (Pubitemid 37407163)
68. Heiniger, C.D.; Kostadinova, R.M.; Rochat, M.K.; Serra, A.; Ferrari, P.; Dick, B.; Frey, B.M.; Frey, F.J. Hypoxia causes downregulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. FASEB J., 2003, 17, 917-919.
69. Nakagami, H.; Jensen, K.S.; Liao, J.K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterolindependent mechanisms. Ann. Med., 2003, 35, 398-403. (Pubitemid 37255462)
70. Davignon, J. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004, 109, 9-43.
71. López-Cuenca, A.; Marín, F.; Roldán, V.; Climent, V.E.; Valdés, M.; Lip, G.Y. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease. Int. J. Cardiol., 2010, 139, 95-97.
72. Simko, F. Statins: a perspective for left ventricular hypertrophy treatment. Eur. J. Clin. Invest. 2007; 37: 681-691. (Pubitemid 47256168)
73. Nishikimi, T.; Tadokoro, K.; Wang, X.; Mori, Y.; Asakawa, H.; Akimoto, K.; Yoshihara, F.; Horio, T.; Minamino, N.; Matsuoka, H. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. Eur. J. Pharmacol., 2002, 453, 175-181. (Pubitemid 35223507)
74. Indolfi, C.; Di Lorenzo, E.; Perrino, C.; Stingone, A.M.; Curcio, A.; Torella, D.; Cittadini, A.; Cardone, L.; Coppola, C.; Cavuto, L.; Arcucci, O.; Sacca, L.; Avvedimento, E.V.; Chiariello, M. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibitis p21ras activation. Circulation, 2002, 106, 2118-2124. (Pubitemid 35192819)
75. Planavila, A.; Laguna, J.C.; Vazquez-Carrera, M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim. Biophys. Acta., 2005, 1687, 76-83. (Pubitemid 40228987)
76. Patel, R.; Nagueh, S.F.; Tsybouleva, N.; Abdellatif, M.; Lutucuta, S.; Kopelen, H.A.; Quinones, M.A.; Zoghbi, W.A.; Entman, M.L.; Roberts, R.; Marian, A.J. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human Hypertrophic cardiomyopathy. Circulation, 2001, 104, 317-324. (Pubitemid 32666954)
77. Bezerra, D.G.; Mandarim-de-Lacerda, C.A. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodel ling and glomeruli loss spontaneously hypertensive rats. Clin. Sci., 2005, 108, 349-355. (Pubitemid 40516998)
78. Yang, L.; Gao, Y.J.; Lee, R.M. The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats. Eur. J. Pharmacol., 2005, 518, 145-151. (Pubitemid 41133638)
79. Bauersachs, J.; Störk, S.; Kung, M.; Waller, C.; Fidler, F.; Hoyer, C.; Frantz, S.; Weidemann, F.; Ertl, G.; Angermann, C.E. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur. J. Clin. Invest., 2007, 37, 852-859. (Pubitemid 350029212)
80. Zhang, G.G.; Zhang, S.D. Effect of simvastatin on cardiac fibrosis in patients with essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2005, 30, 280-282.
81. Su, S.F.; Hsiao, C.L.; Chu, C.W.; Lee, B.C.; Lee, T.M. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am. J. Cardiol., 2000, 86, 514-518.
82. De Koninck, P.; Schulman, H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science, 1998, 279, 227-230. (Pubitemid 28103880)
83. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ, Giewat M, Seidman CE, Seidman JG. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 2000; 106: 1351-1359.
84. Ventura, H.O.; Malik, F.S.; Mehra, M.R.; Stapleton, D.D.; Smart, F.W. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr. Opin. Cardiol., 1997, 12, 375-381. (Pubitemid 27321008)
85. Chang, R.K.; McDiarmid, S.V.; Alejos, J.C.; Drant, S.E.; Klitzner, T.S. Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation. Pediatr. Transplant., 2001, 5, 187-191. (Pubitemid 32545265)
86. 31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: experiences as 3T. Eur. J. Radiol., 2010, 73, 255-259.
87. Criley, J.G.; Boehm, E.A.; Blair, E.; Rajagopalan, B.; Blamire, A.M.; Styles, P.; McKenna, W.J.; Ostman-Smith, J.; Clarke, K.; Watkins, H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol., 2003, 41, 1776-1782. (Pubitemid 36584252)
88. Cole, P.L.; Beamer, A.D.; McGowan, N.; Cantillon, C.O.; Benfell, K.; Kelly, R.A.; Hartley, L.H.; Smith, T.W.; Antman, E.M. Efficacy and safety of perhexiline maleate in refractory angina: a double- blind placebo-controlled clinical trial of a novel antianginal agent. Circulation, 1990, 81, 1260-1270. (Pubitemid 20119624)
89. Jeffrey, F.M.; Alvarez, L.; Diczku, V.; Sherry, A.D.; Malloy, C.R. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J. Cardiovasc. Pharmacol., 1995, 25, 469-472.
90. Kennedy, J.A.; Unger, S.A.; Horowitz, J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol., 1996, 52, 273-280. (Pubitemid 26233756)
91. Hirotani, S.; Otsu, K.; Nishida, K.; Higuchi, Y.; Morita, T.; Nakayama, H.; Yamaguchi, O.; Mano, T.; Matsumura, Y.; Ueno, H.; Tada, M.; Hori, M. Involvement of nuclear factor-kappa B and apoptosis signal-regulating kinase-1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation, 2002, 1050, 509-515. (Pubitemid 34141710)
92. Onai, Y.; Suzuki, J.; Maejima, Y.; Haraguchi, G.; Muto, S.; Itai, A.; Isobe, M. Inhibition of NF-kappa B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, 530-538.
93. Cucoranu, I.; Clempus, R.; Dikalova, A.; Phelan, P.J.; Ariyan, S.; Dikalov, S.; Sorescu, D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res., 2005, 97, 900-907. (Pubitemid 41552675)
94. Marian, A.J.; Senthil, V.; Chen, S.N.; Lombardi, R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J. Am. Coll. Cardiol., 2006, 47, 827-834. (Pubitemid 43243108)
95. McCarty, M.F. Practical prevention of cardiac remodeling and atrial fibrillation with full-spectrum antioxidant therapy and ancillary strategies. Med. Hypotheses, 2010, 75, 141-147.
96. Moens, A.L.; Claeys, M.J.; Wuyts, F.L.; Goovaerts, I.; Van, H.E.; Wendelen, L.C.; Van, H.V.; Vrints, C.J. Effect of folic acid on endothelial function following acute myocardial infarction. Am. J. Cardiol., 2007, 99, 476-481. (Pubitemid 46215548)
97. Robin, E.; Guzy, R.D.; Loor, G.; Iwase, H.; Waypa, G.B.; Marks, J.D.; Hoek, T.L.; Schumacker, P.T. Oxidant stress during simulated ischemia primes cardiomyocytes for cell death during reperfusion. J. Biol. Chem., 2007, 282, 19133-19143. (Pubitemid 47100157)
98. Harker-Murray, A.K.; Tajik, A.J.; Ishikura, F.; Meyer, D.; Burnett, J.C.; Redfield, M.M. The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J. Card. Fail., 2000, 6, 233-242.
99. Kalenikova, E.I.; Gorodetskaya, E.A.; Kolokolchikova, E.G.; Shashurin, D.A.; Medvedev, O.S. Chronic administration of coenzyme Q10 limits postinfarct myocardial remodeling in rats. Biochemistry, 2007, 72, 332-338. (Pubitemid 46571277)
100. Moens, A.L.; Takimoto, E.; Tocchetti, C.G.; Chakir, K.; Bedja, D.; Cormaci, G.; Ketner, E.A.; Majmudar, M.; Gabrielson, K.; Halushka, M.K.; Mitchell, J.B.; Biswal, S.; Channon, K.M.; Wolin, M.S.; Alp, N.J.; Paolocci, N.; Champion, H.C.; Kass, D.A. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation, 2008, 117, 2626-2636.
101. Liu, D.D.; Kao, S.J.; Chen, H.I. N-Acetylcysteine attenuates acute lung injury induced by fat embolism. Crit. Care Med., 2008, 36, 565-571. (Pubitemid 351158634)
102. Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, R.; Jansen, H.M.; MacNee, W.; Thomeer, M.; Wallaert, B.; Laurent, F.; Nicholson, A.G.; Verbeken, E.K.; Verschakelen, J.; Flower, C.D.R.; Capron, F.; Petruzzelli, S.; De Vuyst, P.; van den Bosch, J.M.M.; Rodriguez-Becerra, E.; Corvasce, G.; Lankhorst, I.; Sardina, M.; Montanari, M.; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med., 2005, 353, 2229-2242. (Pubitemid 41697286)
103. Atkuri, K.R.; Mantovani, J.J.; Herzenberg, L.A.; Herzenberg, L.A. N-Acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol., 2007, 7, 355-359. (Pubitemid 47289259)